Business Wire

Tax Systems Launches AI-powered, SaaS Solution for Global Pillar Two Compliance and Reporting

15.1.2025 09:00:00 CET | Business Wire | Press release

Share

Secure, scalable software that ensures organisations are prepared for the challenges of OECD Pillar Two rules now and in the future

Tax Systems, the global multi-tax compliance SaaS provider, has today announced the availability of Pillar2, an intuitive solution to de-risk and simplify compliance with the OECD’s global Pillar Two tax rules. Designed for organisations operating across multiple jurisdictions - Pillar2 will save businesses valuable time and reduce the risk of errors, so they can cost effectively operationalise Pillar Two reporting and comply with confidence.

Pillar2 integrates seamlessly with the provisioning and country-by-country reporting applications on TaxSuite - Tax Systems’ modular platform for international tax compliance. This means organisations can upload information once and re-use it as a single source of truth for their tax compliance data - helping to ensure consistency and accuracy across the tax reporting cycle and strengthen tax control frameworks.

The solution offers a range of innovative features, including a jurisdiction implementation tracker that shows if QDMTT, IIR, or UTPR are in force - this is kept up-to-date by Tax Systems, making it easy for organisations to know which rules are applied, and saving them the need to constantly monitor for changes. The offsets and allocations process is automated, with calculations that can’t be overridden, to further de-risk Pillar Two compliance. A comprehensive audit trail logging all user actions and data changes ensures complete transparency.

In addition to offering robust compliance support, Pillar2's flexible data management means it’s easy to upload information from both centralised systems and local operations, saving time, optimising processes and reducing the risk of errors.

Generative AI capabilities within Pillar2 also gives real-time tax insights, helping professionals to proactively manage risks and optimise their tax processes. Users can ask questions about their Pillar Two numbers, using natural language, receiving instant, data-driven responses. This approach makes it easy to identify and investigate any anomalies, while improving tax-related decision-making.

"Pillar Two compliance has added further complexity to tax professionals’ already heavy workloads, but our solution can take some of the burden by calculating any top-up tax due accurately and efficiently,” said Bruce Martin, CEO of Tax Systems. “Pillar2 has been designed from the ground up to help organisations meet these new global tax reporting requirements, simplify compliance processes and provide useful insights. Armed with the ability to manage their entire tax control framework from a single, fully connected platform, organisations can significantly reduce operational complexity while ensuring accuracy in every step of the compliance process.”

Improved collaboration backed by robust security

Pillar2 also supports organisations wishing to take advantage of co-sourcing - its SaaS capabilities, including role-based access control, ensure that only the right people can access sensitive tax data. This means that multi-nationals can maintain a level of control and collaborate with their advisors on different elements of the Pillar Two process using the same solution and data; rather than outsourcing their entire Pillar Two process.

Furthermore, all data is stored securely in MS Azure with a full audit trail, in keeping with being ISO27001 certified. Based on an organisation’s preference, Pillar2 can be configured for data to be hosted in either the UK or EEA.

“We have created a solution that is fit for purpose now and in the future, ensuring compliance with regulations and legislation as it changes both globally and locally,” concludes Bruce Martin. “The tax logic and calculations in Pillar2 have been built by the same team that supports Alphatax – the number 1 corporation tax compliance software in the UK, Ireland, and UAE. This is the latest solution on our global tax compliance and reporting platform and we’re excited for what is still to come. Tax compliance is always evolving and growing in complexity, and we are committed to advancing tax technology and supporting the global tax digitisation agenda.”

To learn more about Pillar2, click here.

About Tax Systems

Tax Systems, a Bowmark Capital-backed investment, is a global multi-tax compliance SaaS provider, with market-leading solutions across the UK, Ireland, Europe and the UAE. Its solutions digitise tax processes and revolutionise compliance operations, enabling tax professionals to create better opportunities and generate valuable insights from their tax function while also mitigating risk. Translating complex, ever-changing tax legislation into intuitive solutions, customers can trust that their calculations will be right, first-time, every time.

Founded in 1991, Tax Systems has over 30 years’ experience and works with over 42% of the FTSE 100 and 80% of the top advisory firms in the UK and Ireland, where more than 30,000 tax professionals are trained to use their solutions, filing over 200,000 submissions every year.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250115190834/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye